Leila Motedayen Aval

1 month ago | onlinelibrary.wiley.com | Oras A Alabas |Nick Reynolds |Philip Hampton |Leila Motedayen Aval

Why was the study undertaken? This study was undertaken to address gaps left by randomized controlled trials in comparing the effectiveness of IL-23p19 and IL-17 inhibitors, specifically risankizumab and brodalumab, against each other in a representative clinical population. What does this study add? We showed that IL-23p19 inhibitors have the highest drug survival, with patients persisting 21weeks longer for effectiveness and 13weeks for safety over 2 years.